Proactive Investors - Run By Investors For Investors

Scancell strengthens IP with two “important” patent grants in US and Europe

The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88
test tubes in laboratory
Scancell is developing drugs that harness the body’s immune system to attack cancers

Scancell Holdings PLC (LON:SCLP) has strengthened its intellectual property (IP) after it was granted two “important” patents in the US and Europe.

The US patent covers Modi-1 – the first clinical candidate from Scancell’s Moditope immunotherapy platform.

It claims methods of stimulating an immune response to a tumour and methods of treating cancer using peptides of Modi-1.

READ: Scancell lauds another six months of progress

Similar protection has already been granted in Europe, South Africa, and Australia, as well as acceptance for grant in China.

As for the European patent announced today, that relates to FG88, a monoclonal antibody directed to tumour associated glycans, which Scancell said further strengthens the commercial positioning of its monoclonal antibody development programme.

“We are pleased to have been granted these two important patents for our immunotherapy platforms in the United States and Europe,” said chief executive Cliff Holloway.

“This Moditope patent provides protection for Modi-1 in the US and further endorses the novelty of Scancell's work in identifying a new class of cancer vaccine.”

He added: “Through the continued expansion of our intellectual property portfolio in the US and Europe, we believe we are well positioned to advance our pipeline of novel immunotherapies.”

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
consumer health segment overview
January 10 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use